Back to Authors

Ali, Sajid

https://orcid.org/0000-0002-0696-3057

A5046303624 | I4210150756

AstraZeneca (United States)

Citations 2

Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Future Oncology | September 6, 2023 | Volume: 19 | Issue: 38 | Pages: 2505-2516

10.2217/fon-2023-0486 | PMID 37671641

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

NEJM Evidence | June 6, 2022 | Volume: 1 | Issue: 8 | Pages: No page available

10.1056/evidoa2100070 | PMID 38319892